Background: There are not so many articles about treatment of pulmonary embolism (PE) with lowe molecular weight heparin (LMWH). Aim of Study: Comparision of efficacy and safety treatment of PE with LMWH (enoxaparin), and standard unfractionated heparin (UFH)on clinical sample. Patients and Methods: We compared two groups pts with PE. In the groups there was 38 pts (18 m and 20 f, age 58,2 12.4, 57.5% smokers and 13.4% ex smokers) who treated with LMWH 1mg/kg/24h. In second group there was 36 pts (15m and 21 f, age 59.1r 11.9, 54% smokers and 11.5% ex smokers) who was treated with classic heparin 40000 IU/14h. Parametres for evaluation efficacy and safety of BE treatment elaborated with calculating means and paired-samples t-test (Student and Chi square test) Results: Analysis of risk factors which was attend in both groups showed that there was not statisticalsignificant differences (SSD) between pts of both groups (F2 =0.267, p=0.6). The regression of clinical, radiological and significant signs of PE was some faster in group which was treated with LMWH, but there was not SSD between this group pts and group treated with UFH (Student t-test = -0.96, p=0,23). Also, in anlysis of treatment complication there was no SSD between two groups. Price of treatment with LMWH was doubly reduced-clear cost benefit.
Conclusion: It looks that LMWH - enoxaparin making faster effects in treatment PE with less complications, but in our study we are not approved existence SSD in efficacy and safety in comparation with gropup pts treated with UFH . But treatment with LMWH in our situation is more than doubly cheaper than with UFH.